CNTX
Context Therapeutics Inc.
Biotechnology · Healthcare · United States
0.19
close · 2026-10-30
value
3
cheaper than peers3
quality
63
stronger fundamentals63
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.46× | 95 |
| cash flow yield, 3 years ago | -81.1% | 16 |
| cash flow yield, 2 years ago | -121.1% | 10 |
| cash flow yield, 1 year ago | -168.7% | 9 |
| earnings yield, latest year | -201.0% | 8 |
| earnings yield, 1 year ago | -243.3% | 8 |
| cash flow yield, latest year | -163.6% | 5 |
| earnings yield, 3 years ago | -491.8% | 4 |
| earnings yield, 2 years ago | -793.2% | 1 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.6% | 80 |
| operating margin | 0.0% | 50 |
| return on equity | -76.1% | 41 |
3 of 4 measures available
Facts
| market cap | $17M |
| free cash flow | -$31.5M |
| employees | 15 |
| first trade | 2021-10-20 |
| next earnings | not reported |
| fundamentals updated | 2026-08-14 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -0.38 | -0.46 | -1.50 | -0.93 | not reported |
| free cash flow | -$28.4M | -$29.3M | -$21.0M | -$14.1M | not reported |
| net income | -$36.1M | -$26.7M | -$24.0M | -$14.8M | not reported |
| revenue | $0 | $0 | $0 | $0 | not reported |
| unusual items | not reported | not reported | $0 | -$500,000 | -$3.1M |